

**Date: January 15, 2025**

**BSE Limited**

P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)**

---

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received an Order on January 14, 2025 from Office of the Commissioner of Kolkata South CGST & CX– issued by Additional Commissioner (“Department”) under Section 74 of the CGST Act, 2017. Based on the assessment of facts and prevailing law, the Company is of the view that the aforesaid order is arbitrary and unjustified. The Company will file necessary appeal with the appellate authority in this regard. There is no material impact on financials, operations or other activities of the Company.

The detailed disclosure as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 for aforesaid is enclosed as annexure I.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Jain**  
Company Secretary and Compliance Officer

## Annexure – I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Additional Commissioner, Central Tax, CGST& CX Kolkata (“Department”)
2	Nature and details of the action(s) taken, initiated or order(s) passed;	Order-in-Original passed u/s 74 of Central Goods and Services Tax Act, 2017 covering FY 2017-18 to FY2021-22 levying penalty of INR 2,27,83,935/-.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	Order dated December 26, 2024 received on 14 January, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	The GST Authority has passed the Order, pursuant to GST audit for the FY 2017-18 to FY 2021-22 on the contention that there is a mismatch in the figures reported in various statutory returns Viz. GSTR-9, GSTR-3B, GSTR-1 and GSTR -2A.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	<p>Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified.</p> <p>The Company does not agree with the order and will take appropriate action(s) for the same including filing of an appeal if required.</p> <p>There is no material impact on the company's financials, operations, or other activities.</p>

**MANKIND PHARMA LIMITED**